TABLE 1

In vitro antibacterial activities of lascufloxacin against various clinical isolates

Organisma (no. of isolates)DrugMIC (μg/ml)
RangeMIC50MIC90
MSSA (30)Lascufloxacin≤0.008 to 0.0150.0150.015
Levofloxacin0.12 to 0.250.250.25
Garenoxacin≤0.008 to 0.030.0150.03
Azithromycin1 to >642>64
Ceftriaxone2 to 424
Cefcapene1 to 212
Meropenem≤0.06 to 0.12≤0.06≤0.06
Oxacillin0.12 to 10.250.5
MRSA (100)Lascufloxacin0.03 to 20.52
Levofloxacin0.25 to >12864>128
Garenoxacin0.06 to 64864
Ciprofloxacin0.5 to >128128>128
Ceftazidime16 to >128>128>128
Imipenem0.06 to >12832128
Vancomycin0.5 to 211
Teicoplanin0.5 to 814
Oxacillin16 to >128>128>128
Arbekacin0.25 to 812
Daptomycin0.25 to 10.50.5
Linezolid1 to 422
S. epidermidis (30)Lascufloxacin0.015 to 0.120.030.12
Levofloxacin0.12 to 80.254
Garenoxacin0.03 to 10.061
Azithromycin0.25 to >640.5>64
Ceftriaxone1 to >128432
Cefcapene0.12 to >1280.58
Meropenem≤0.06 to 320.54
Oxacillin≤0.06 to >128132
E. faecalis (30)Lascufloxacin0.06 to 0.50.060.12
Levofloxacin1 to >1612
Garenoxacin0.12 to 20.120.25
Azithromycin4 to >64>64>64
Ceftriaxone64 to >128>128>128
Cefcapene64 to >128>128>128
Meropenem2 to 848
S. pyogenes (30)Lascufloxacin0.03 to 0.120.030.06
Levofloxacin0.5 to 20.51
Garenoxacin0.03 to 0.120.060.12
Azithromycin0.12 to >160.1216
Ceftriaxone0.0150.0150.015
Cefcapene≤0.008≤0.008≤0.008
Meropenem≤0.008≤0.008≤0.008
S. agalactiae (30)Lascufloxacin0.06 to 10.060.5
Levofloxacin0.5 to >161>16
Garenoxacin0.06 to 40.064
Azithromycin0.06 to >160.06>16
Ceftriaxone0.06 to 0.250.060.12
Cefcapene0.03 to 0.120.030.06
Meropenem0.03 to 0.060.030.06
PSSP (30)Lascufloxacin0.03 to 0.060.060.06
Levofloxacin0.5 to 111
Garenoxacin0.03 to 0.060.060.06
Azithromycin0.03 to >16>16>16
Ceftriaxone0.015 to 0.250.120.25
Cefcapene≤0.008 to 0.50.250.5
Meropenem≤0.008 to 0.015≤0.0080.015
Benzylpenicillin0.015 to 0.060.030.06
PRSP (30)Lascufloxacin0.03 to 0.060.060.06
Levofloxacin0.5 to 111
Garenoxacin0.03 to 0.060.060.06
Azithromycin1 to >16>16>16
Ceftriaxone0.5 to 412
Cefcapene0.5 to 412
Meropenem0.25 to 10.51
Benzylpenicillin2 to 424
E. coli (30)Lascufloxacin0.06 to >160.25>16
Levofloxacin0.015 to >160.0616
Garenoxacin0.015 to >160.12>16
Azithromycin4 to 64864
Ceftriaxone≤0.06 to >128≤0.06>128
Cefcapene0.25 to >1280.5128
Meropenem≤0.06≤0.06≤0.06
Enterobacter spp. (30)Lascufloxacin0.12 to 0.50.250.25
Levofloxacin0.03 to 0.060.060.06
Garenoxacin0.06 to 0.250.120.12
Azithromycin8 to 321616
Ceftriaxone≤0.06 to 320.1216
Cefcapene0.5 to 320.532
Meropenem≤0.06 to 0.12≤0.06≤0.06
K. pneumoniae (30)Lascufloxacin0.12 to 0.50.250.25
Levofloxacin0.03 to 0.120.060.06
Garenoxacin0.06 to 0.250.120.12
Azithromycin8 to 161616
Ceftriaxone≤0.06≤0.06≤0.06
Cefcapene0.25 to 10.51
Meropenem≤0.06≤0.06≤0.06
Acinetobacter spp. (30)Lascufloxacin0.06 to 160.250.5
Levofloxacin0.03 to 80.060.25
Garenoxacin0.015 to 80.030.12
Azithromycin0.5 to >64164
Ceftriaxone2 to >128816
Cefcapene4 to 1281616
Meropenem0.12 to 20.250.5
P. aeruginosa (30)Lascufloxacin1 to >164>16
Levofloxacin0.25 to >160.5>16
Garenoxacin0.5 to >161>16
Azithromycin8 to >6464>64
Ceftriaxone8 to >12832>128
Cefcapene16 to >12832>128
Meropenem0.12 to 640.258
M. catarrhalis (30)Lascufloxacin0.06 to 0.120.060.06
Levofloxacin0.030.030.03
Garenoxacin≤0.008 to 0.015≤0.0080.015
Azithromycin≤0.06 to 0.12≤0.06≤0.06
Ceftriaxone≤0.06 to 10.51
Cefcapene≤0.06 to 10.51
Meropenem≤0.06≤0.06≤0.06
BLNAS (30)Lascufloxacin0.03 to 0.060.030.06
Levofloxacin0.015 to 0.030.0150.03
Garenoxacin≤0.004 to 0.0150.0080.015
Azithromycin0.5 to 412
Ceftriaxone≤0.008 to 0.25≤0.0080.25
Cefcapene≤0.008 to 20.0151
Meropenem0.015 to 0.060.030.06
Ampicillin0.12 to 10.51
BLNAR (30)Lascufloxacin0.03 to 0.120.030.06
Levofloxacin0.015 to 0.060.0150.03
Garenoxacin≤0.004 to 0.030.0080.015
Azithromycin0.5 to 412
Ceftriaxone0.03 to 0.250.250.25
Cefcapene0.12 to 222
Meropenem0.03 to 0.50.250.25
Ampicillin2 to 844
M. pneumoniae (50)Lascufloxacin0.06 to 0.250.120.25
Levofloxacin0.25 to 0.50.50.5
Garenoxacin0.008 to 0.030.0150.03
Clarithromycin≤0.001 to >16>16>16
Azithromycin≤0.001 to 16816
  • a PSSP and PRSP, penicillin-susceptible and penicillin-resistant S. pneumoniae, respectively; BLNAS and BLNAR, β-lactamase-negative ampicillin-susceptible and ampicillin-resistant strains of Haemophilus influenzae, respectively.